Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.

Summary, in English

Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin). However, there are uncertainties regarding the risk for thrombosis since poor-responsiveness to clopidogrel is common. Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited. This study therefore sought to evaluate the risk of bleeding and thrombosis associated with DT after an acute coronary syndrome (ACS).

• Author: Oscar Braun; Besim Bico; Uzma Chaudhry; Henrik Wagner; Sasha Koul; Patrik Tydén; Fredrik Scherstén; Stefan Jovinge; Peter Svensson; Gustav Smith; Jesper vanderPals
• Department/s: Cardiology; Cardiovascular Research - Epidemiology; Stem Cell Center; Clinical Coagulation, Malmö; Arrhytmias and Cardiac Device treatment; Molecular Cardiology; EXODIAB: Excellence of Diabetes Research in Sweden; EpiHealth: Epidemiology for Health
• Publishing year: 2015
• Language: English
• Pages: 26-30
• Publication/Series: Thrombosis Research
• Volume: 135
• Issue: 1
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25467434?dopt=Abstract; http://dx.doi.org/10.1016/j.thromres.2014.10.016
• Document type: Journal article
• Publisher: Elsevier
• Topic: Cardiac and Cardiovascular Systems
• Status: Published
• Research group: Cardiovascular Research - Epidemiology; Clinical Coagulation, Malmö; Arrhytmias and Cardiac Device treatment; Molecular Cardiology
• ISBN/ISSN/Other: ISSN: 1879-2472